Compare LUNG & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | ONCY |
|---|---|---|
| Founded | 1995 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.1M | 80.5M |
| IPO Year | 2020 | 2002 |
| Metric | LUNG | ONCY |
|---|---|---|
| Price | $2.53 | $0.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $3.70 | ★ $4.20 |
| AVG Volume (30 Days) | 279.2K | ★ 1.2M |
| Earning Date | 10-27-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,497,000.00 | N/A |
| Revenue This Year | $0.06 | N/A |
| Revenue Next Year | $8.58 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.01 | N/A |
| 52 Week Low | $1.13 | $0.44 |
| 52 Week High | $2.66 | $1.30 |
| Indicator | LUNG | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 77.09 | 25.32 |
| Support Level | $1.20 | N/A |
| Resistance Level | N/A | $0.89 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 85.71 | 1.09 |
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.